Technical Analysis for 0W4N - Formycon AG
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Boomer Sell Setup | Bearish Swing Setup | 0.46% | |
| NR7 | Range Contraction | 0.46% | |
| Narrow Range Bar | Range Contraction | 0.46% | |
| Inside Day | Range Contraction | 0.46% | |
| Gapped Up | Strength | 0.46% | |
| Oversold Stochastic | Weakness | 0.46% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 1 day ago |
| Outside Day | 1 day ago |
| Boomer Sell Entry | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
| Possible Inside Day | 4 days ago |
Free Daily (Stock) Chart Reading
Formycon AG Description
Formycon AG develops and markets biosimilar products in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema and myopic choroidal neovascularization under the Ranivisio, ONGAVIA, and CIMERLI names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of chronic inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea, that treats neovascular age-related macular degeneration and serious retinal diseases that is in Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of cancer; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
Classification
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 80.2 |
| 52 Week Low | 37.85 |
| Average Volume | 885 |
| 200-Day Moving Average | 55.38 |
| 50-Day Moving Average | 47.21 |
| 20-Day Moving Average | 43.30 |
| 10-Day Moving Average | 40.48 |
| Average True Range | 1.22 |
| RSI (14) | 32.43 |
| ADX | 31.33 |
| +DI | 16.47 |
| -DI | 42.12 |
| Chandelier Exit (Long, 3 ATRs) | 43.45 |
| Chandelier Exit (Short, 3 ATRs) | 41.51 |
| Upper Bollinger Bands | 49.85 |
| Lower Bollinger Band | 36.75 |
| Percent B (%b) | 0.22 |
| BandWidth | 30.24 |
| MACD Line | -2.33 |
| MACD Signal Line | -2.02 |
| MACD Histogram | -0.3126 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 40.18 | ||||
| Resistance 3 (R3) | 40.15 | 39.95 | 40.09 | ||
| Resistance 2 (R2) | 39.95 | 39.82 | 39.96 | 40.06 | |
| Resistance 1 (R1) | 39.80 | 39.73 | 39.88 | 39.83 | 40.03 |
| Pivot Point | 39.60 | 39.60 | 39.64 | 39.61 | 39.60 |
| Support 1 (S1) | 39.45 | 39.47 | 39.53 | 39.48 | 39.27 |
| Support 2 (S2) | 39.25 | 39.38 | 39.26 | 39.24 | |
| Support 3 (S3) | 39.10 | 39.25 | 39.21 | ||
| Support 4 (S4) | 39.13 |
